<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>[REDACTED] Progress Note</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Assessment</a></li><li><a href="#id2">Allergies and Adverse Reactions</a></li><li><a href="#id3">Plan</a></li><li><a href="#id4">Reason for Visit</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Immunizations</a></li><li><a href="#id7">Diagnostic Results</a></li><li><a href="#id8">Medications</a></li><li><a href="#id9">Problems</a></li><li><a href="#id10">Vital Signs</a></li><li><a href="#id11">Notes Section</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Assessment</a></h3><div>See Clinical Notes section</div><h3><a name="id2" href="#toc">Allergies and Adverse Reactions</a></h3><div><table>
    <thead>
        <tr>
                            <th>Medication/Group Name</th>
                <th>Reaction</th>
                <th>Severity</th>
                <th>Date</th>
        </tr>
    </thead>
    <tbody>
                <tr ID="AlertOBS-1000">
                    <td colspan="4">No known allergies</td>
                </tr>
    </tbody>
</table>
</div><h3><a name="id3" href="#toc">Plan</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="CarePlanRef-1001">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1002">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CMP</td>
				</tr>
				<tr ID="CarePlanRef-1003">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>PSA</td>
				</tr>
				<tr ID="CarePlanRef-1004">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Testosterone, total</td>
				</tr>
				<tr ID="CarePlanRef-1005">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>C-reactive protein (CRP), cardiac</td>
				</tr>
				<tr ID="CarePlanRef-1006">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id4" href="#toc">Reason for Visit</a></h3><div>FOLLOW UP</div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="EncounterDiagnosisRef-1007">
							<td>[REDACTED]</td>
							<td>Hormone sensitive malignancy status</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1008">
							<td>[REDACTED]</td>
							<td>Metastatic prostate cancer</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1009">
							<td>[REDACTED]</td>
							<td>Pathological fracture due to osteoporosis</td>						
					</tr>
	</tbody>
</table>
</div><h3><a name="id6" href="#toc">Immunizations</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Instructions</th>
				<th>Refusal Reason</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
				<tr><td colspan="7">No data for this encounter</td></tr>
	</tbody>
</table>
</div><h3><a name="id7" href="#toc">Diagnostic Results</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Test</th>
				<th>Units</th>
				<th>Lower Limit</th>
				<th>Upper Limit</th>
				<th>Result</th>
				<th>Flag</th>
				<th>Comments</th>
				<th>Status</th>
				<th>Ordered By</th>
				<th>Specimen Source</th>
				<th>Lab Address</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="13">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id8" href="#toc">Medications</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Frequency</th>
				<th>Instructions</th>
				<th>Start Date</th>
				<th>End Date</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="MedicationOBS-1010">
							<td/>
							<td>Metformin Oral </td>
							<td>orally</td>
							<td>500.0 mg</td>
							<td>2 times per day</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1011">
							<td/>
							<td>Atorvastatin Oral </td>
							<td>orally</td>
							<td>40.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1012">
							<td/>
							<td>Clopidogrel Oral </td>
							<td>orally</td>
							<td>75.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1013">
							<td/>
							<td>Levothyroxine Oral </td>
							<td>orally</td>
							<td>50.0 mcg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1014">
							<td/>
							<td>Olmesartan Oral </td>
							<td>orally</td>
							<td>20.0 mg</td>
							<td>daily</td>
							<td>prn</td>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1015">
							<td>[REDACTED]</td>
							<td>1.5 ML leuprolide acetate 7.5 MG/ML Prefilled Syringe </td>
							<td>intramuscularly</td>
							<td>45.0 mg</td>
							<td/>
							<td/>
							<td>[REDACTED]</td>
							<td>[REDACTED]</td>
							<td>on hold</td>
					</tr>
	</tbody>
</table>
</div><h3><a name="id9" href="#toc">Problems</a></h3><div><table>
	<thead>
		<tr>
							<th>Diagnosis</th>
				<th>Status</th>
				<th>Date of Diagnosis</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="ProblemOBS-1016">
						<td>Pathological fracture due to osteoporosis</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1017">
						<td>UTI</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1018">
						<td>Hormone sensitive malignancy status</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1019">
						<td>Metastatic prostate cancer</td>
						<td>Active</td>
						<td/>
				</tr>
	</tbody>
</table>
</div><h3><a name="id10" href="#toc">Vital Signs</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="VitalSignsRef-1020">
						<td>[REDACTED]</td>
						<td>
							Body Temperature
							
						</td>
						<td>97.20</td>
				</tr>
				<tr ID="VitalSignsRef-1021">
						<td>[REDACTED]</td>
						<td>
							Heart Beat
							
						</td>
						<td>105.00</td>
				</tr>
				<tr ID="VitalSignsRef-1022">
						<td>[REDACTED]</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>16.00</td>
				</tr>
				<tr ID="VitalSignsRef-1023">
						<td>[REDACTED]</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>98.00</td>
				</tr>
				<tr ID="VitalSignsRef-1024">
						<td>[REDACTED]</td>
						<td>
							BSA
							
						</td>
						<td>1.80</td>
				</tr>
				<tr ID="VitalSignsRef-1025">
						<td>[REDACTED]</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1026">
						<td>[REDACTED]</td>
						<td>
							Weight
							
						</td>
						<td>177.80</td>
				</tr>
				<tr ID="VitalSignsRef-1027">
						<td>[REDACTED]</td>
						<td>
							Height
							
						</td>
						<td>61.00</td>
				</tr>
				<tr ID="VitalSignsRef-1028">
						<td>[REDACTED]</td>
						<td>
							BMI
							
						</td>
						<td>33.59</td>
				</tr>
				<tr ID="VitalSignsRef-1029">
						<td>[REDACTED]</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>150</td>
				</tr>
				<tr ID="VitalSignsRef-1030">
						<td>[REDACTED]</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>84</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id11" href="#toc">Notes Section</a></h3><div>	<ul><li>
		        Follow-Up: 
		        <p>
		        		

<br/>[REDACTED]<br/>
Suite 210<br/>
[REDACTED]

<br/>
<br/>Phone: [REDACTED] Fax: [REDACTED]


<br/>


<br/>Patient Name: [REDACTED]

<br/>Date of Birth: [REDACTED]

<br/>Medical Record #: [REDACTED]

<br/>Attending Physician: [REDACTED], MD

<br/>Location: 			[REDACTED]

<br/>Referring Physician: [REDACTED] NP-C

<br/>


<br/>Follow-Up

<br/>Date of Visit: [REDACTED]

<br/>
<br/>Reason for f/up [REDACTED]<br/>Main Problem: Prostate Ca  (initial stage T1c) though intermediate unfavorable [REDACTED] score 4+3 = 7, [REDACTED], and PSA 19.3 at presentation, s/p EBRT  and ADT [REDACTED]-[REDACTED]; <br/>- Recurrence since [REDACTED] until [REDACTED] when bone metastases were found, s/p Lupron and Cabozitaxel x1 cycles (info gap if the patient received Docetaxel prior to cabozitaxel).<br/> treatment with either Abiraterone or Xtandi since both of the agents are mentioned in prior records. Lupron stopped in [REDACTED].<br/>- Review of recent blood work\ and PSMA/CT/PET scan of the prostate ( [REDACTED]); <br/>1. Abnormal PET/CT GA68 PSMA LOCAMETZ scan with few enlarged lymph nodes seen in the distal left common iliac, left external iliac and the retroperitoneum most consistent with metastatic adenopathy in this patient with history of prostate cancer and rising PSA levels.<br/>2. No focal uptake is seen in the prostate gland and correlate with MRI prostate.<br/>3. No abnormal uptake in the osseous structures to suggest osseous metastasis.<br/>4. Few tiny subcentimeter pulmonary nodules on the low-dose CT images and follow-up with CT chest [REDACTED].<br/>No prior studies are submitted for comparison<br/>- Previous DEXA scan, back in [REDACTED] revealed osteopenia. <br/>- The germinal mutation analysis ([REDACTED]), did not provide any actionable mutation; <br/>alertness for his cardiac problems in view of prior MI, which implies to take in consideration that decline of the testosterone which may affect the already compromised cardiac function. - Review of the prostate MRI [REDACTED], showed small prostae gland without suspicious lesions to suggest high grade prostate cancer (PI-RADS 2)<br/>- As far as concern the PSA was found to be almost doubled 11.54 ng/ml, prev(6.47 ng/ml), ([REDACTED]), which is slightly more than that of [REDACTED] (6.3 ng/ml).<br/>- Testosterone 348 ( [REDACTED]) ng/dL ( prev 291, [REDACTED])<br/>

<br/>History of Present Illness

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>[REDACTED] was diagnosed with prostate Ca on [REDACTED]; In his R-apex the tumor was [REDACTED] score 3+3; in 4 cores on the L-side the [REDACTED] score was 4+3=7; in the L-lateral apex the core biopsy was reported as a high grade prostate intraepithelial neoplasia. The PSA at presentation was 19.3 ng/ml.<br/>The T-stage was defined as T1c. Based on these info: the tumor is characterized <br/>unfavorable intermediate: Grade group 3, PSA of 10-20 ng/ml (19.3 ng/ml). <br/>The recommended approach is EBRT + ADT ( in case that no surgery is planned).<br/>Despite being young at the time of diagnosis ([REDACTED]), he did not proceed to surgery because he has CAD. Instead, he received definite radiotherapy (8100cGy) and Lupron  from [REDACTED] to [REDACTED], when at that time his PSA became undetectable.<br/>In the same month ([REDACTED]), he was diagnosed with Radiation proctitis, treated with intrarectal formalin for pain relief; additional relief has experienced by swimming in the ocean ( [REDACTED]) and by purchasing a bidet for his toilet called the FreshSpa; he has eventually developed rectal abscess <br/>On [REDACTED], his PSA was 0.07 and the Testosterone 184; both were parallelly increased to reach testosterone 393 on [REDACTED] while the PSA was 1.15.<br/>Further increase in the PSA on [REDACTED]: at 2.36.  <br/>MRI imaging indicated suspicious recurrence within the prostate gland and was considered for possible salvage prostatectomy. <br/>In consultation with [REDACTED] the procedure was characterized as too risky and advised to have cryoablation. It is not clear if indeed proceeded to the cryoablation.<br/>In [REDACTED], MRI imaging revealed a new 5 mm common iliac LN.<br/>He performed a Blue Earth scan ( [REDACTED]), disclosed 2 areas of metastatic disease one in proximal iliac and the other in the L-periaortic regions, c/w metastatic prostate cancer; <br/>On [REDACTED] he was started on cabazitaxel along with [REDACTED], though this was not tolerated, coincided with the development of perirectal abscess <br/>There are reports indicating that was started on Xtandi but since the insurance did not approved it he remained for a while? on Abiraterone.<br/>He last received Lupron - 2019<br/>Prolia started [REDACTED] (1st dose) [REDACTED], 2nd dose - every 6 months . <br/>f/u - [REDACTED]  - reevaluation  Bone scan -results no evidence of bone lesions.<br/> PSA 1.68 ([REDACTED]) and Testosterone 362 ng/dL<br/>Now we are observing asymptomatic rising PSA.<br/>most recent PSA at 6.47 prev 5.5<br/>fup/up [REDACTED]<br/>Review of recent blood work, and MRI of the prostate; latest DEXA scan, back in [REDACTED] revealed osteopenia. <br/>The patient's main problem is that of metastatic prostate cancer, currently stable<br/>The germinal mutation analysis ([REDACTED]), did not provide any actionable mutation; continue  alertness for his cardiac problems in view of prior MI, which implies to take in consideration that decline of the testosterone which may affect the already compromised cardiac function. <br/>Review of the prostate MRI [REDACTED], showed small prostae gland without suspicious lesions to suggest high grade prostate cancer (PI-RADS 2)<br/>Continue interval decrease in size of the previously seen hematoma adjacent to the anterior aspect of the urinary bladder measuring 15x50 mm.; abnormal enhancement of the distal R-ureter likely representing inflammation related to previously seen calculus the evaluation of which is limited on MRI; the concluding comment was that low-grade prostate cancer cannot be evaluated effectively by MRI. <br/>As far as concern the PSA was found to be elevated to 6.47 ng/ml, ([REDACTED]), which is slightly more than that of [REDACTED] (6.3 ng/ml).<br/>Testosterone levels were low normal at 291 ng/dL<br/>Overall stable condition <br/>










<br/>Medical History<br/>1.- Prostate Ca  (initial stage T1c) though intermediate unfavorable [REDACTED] score 4+3 = 7, [REDACTED], and PSA 19.3 at presentation, s/p EBRT  and ADT [REDACTED]-[REDACTED]; <br/>- Recurrence since [REDACTED] until [REDACTED] when bone metastases were found, s/p Lupron and Cabozitaxel x1 cycles ( info gap if the patient received Docetaxel prior to cabozitaxel). <br/>Another info gap duration of treatment with either Abiraterone or Xtandi since both of the agents are mentioned in prior records. Lupron stopped in [REDACTED].<br/>Most recent  PSA at 6,47 prev 5.5, prev 1.68 and testosterone at 374 prev 362. <br/>As per latest PET/CT GA68 PSMA LOCAMETZ scan ([REDACTED]) revealed: few enlarged lymph nodes seen in the distal left common iliac, left external iliac and the retroperitoneum most consistent with metastatic adenopathy in this patient with history of prostate cancer and rising PSA levels.<br/>- No focal uptake is seen in the prostate gland and correlate with MRI prostate.<br/>- No abnormal uptake in the osseous structures to suggest osseous metastasis.<br/>- As far as concern the PSA was found to be almost doubled 11.54 ng/ml, prev(6.47 ng/ml),     ([REDACTED]), which is slightly more than that of [REDACTED] (6.3 ng/ml).<br/>- Testosterone 348 ( [REDACTED]) ng/dL ( prev 291, [REDACTED])<br/>2.- Osteoporosis; patient on prolia (started on [REDACTED]); unconfirmed info for osteoporosis and fx L/S s/p fall; ? of kyphoplasty ( scheduled not done)<br/>3.- CAD, coronary atherosclerosis., CABG in [REDACTED]<br/>4.- Diabetes type 2<br/>5.- Obesity stage 1<br/>6.- Hypothyroidism<br/>7.- HTN<br/>8.- Hyper/dyslipidemia<br/>9.- Compromised physical condition <br/>10.- ED/impotence ( multifactorial) and depression <br/>11.- Candidate for germline mutation analysis in view of his diagnosis of prostate cancer and the sister with brain cancer ( glioblastoma ?) / analysis<br/>Guardant test - evaluate molecular genomics, uncertain if useful at this time<br/>12.- Frequent UTIs<br/>13.- Radiation proctitis and abscess resolved<br/>

<br/>Surgical History<br/>
   

<br/>


<br/>Medications<br/>
Levothyroxine Oral 25 mcg orally daily, <br/>Metformin Oral 500 mg orally 2 times per day, <br/>Famotidine Oral 20 mg orally daily, <br/>Bayer Chewable Aspirin (Aspirin Oral) 1 tablet orally once a day , <br/>Olmesartan Oral 10 mg orally daily prn, <br/>Atorvastatin Oral 20 mg orally daily, <br/>Clopidogrel Oral 75 mg orally daily, <br/>Biotin Oral 2500 mcg orally daily, <br/>Tamsulosin Oral

<br/>

<br/>Smoking History<br/>


<br/>Never smoker

<br/>


<br/>Social History

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>Alcohol Use: none

<br/>Recreational Drug Use: none

<br/>
<br/>Marital Status: married

<br/>Children: 1<br/>












<br/>Family History<br/>
   

<br/>


<br/>Allergies<br/>
No known medication allergies

<br/>


<br/>Review of Systems

<br/>Constitutional: Denies fever, weight loss, fatigue

<br/>Eyes: Denies visual changes

<br/>ENT/Mouth: Denies hearing problems, oral problems

<br/>Cardiovascular: Denies chest pain, palpitations

<br/>Respiratory: Denies shortness of breath, cough

<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea

<br/>Genitourinary: Denies burning, pain on urination, blood in urine, incontinence

<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain

<br/>Skin: Denies rashes, itchiness, ulcers

<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbness

<br/>Psychiatric: Denies depression, anxiety

<br/>Hematologic/Lymphatic: Denies other bleeding, bruising, swollen lymph nodes


<br/>


<br/>Physical Examination

<br/>Blood pressure: 150/84, R arm, Regular, Pulse: 105, Temperature: 97.2 F, Respirations: 16, O2 sat: 98%, At Rest, Room Air, Pain Scale: 0, Height: 61 in, Weight: 177.8 lb, BSA: 1.8, BMI: 33.59 kg/m2

<br/>General:                   Alert &amp; oriented, no acute distress<br/>Skin:                        Normal<br/>HEENT:                    Pupils equal, round. Oral cavity, oropharynx clear<br/>Neck:                       Supple, no mass<br/>Lungs:                     Clear to auscultation, bilaterally<br/>Heart:                      Regular rate and rhythm, no murmurs, rubs or gallops<br/>Back:                       Nontender<br/>Abdomen:               Soft, nontender, nondistended, no masses palpable, No HSM normal BS<br/>Genitourinary:        Deferred<br/>Extremities:            No clubbing, cyanosis, or edema

<br/>


<br/>Laboratory<br/>
<br/>CBC<br/>
([REDACTED]) WBC x 10^3/uL : 7.3; RBC x 10^6/uL : 4.69; HGB g/dL : 13.9; HCT % : 42.0; MCV fL : 89.6; MCH pg : 29.6; MCHC g/dL : 33.1; RDW % : 13.4; PLT x 10^3/uL : 287; MPV fL : 10.8; Neu % : 59.3; LY % : 26.3; MO % : 8.1; EO % : 5.6; BA % : 0.7; NEU #, cells/uL : 4329; LY #, cells/uL : 1920; MO #, cells/uL : 591; EO #, cells/uL : 409; BA #, cells/uL : 51

<br/>
<br/>Manual Differential<br/>
([REDACTED]) NRBC, #/100 wbc : DNR; NRBC, absolute, cells/uL (M) cells/uL : DNR; Band % : DNR; Promyelocyte % : DNR; Bands, absolute, cells/uL : DNR; Promyelocyte, absolute, cells/uL : DNR

<br/>CMP<br/>
([REDACTED]) C-reactive protein (CRP), cardiac, mg/L : 2.5

<br/>Tumor Markers<br/>
([REDACTED]) CEA ng/mL : 1.2; PSA ng/mL : 11.54 (H)

<br/>

<br/>

<br/>

<br/>Hormones<br/>
([REDACTED]) Testosterone, total ng/dL : 348; Testosterone, free pg/mL : 32.7

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>Other<br/>
([REDACTED]) CBC Comments : DNR; ABSOLUTE BLASTS : DNR; ABSOLUTE METAMYELOCYTES : DNR; ABSOLUTE MYELOCYTES : DNR; BLASTS : DNR; METAMYELOCYTES : DNR; MYELOCYTES : DNR; REACTIVE LYMPHOCYTES : DNR; Clinical PDF Report EN406296Y-1 : See attached


<br/>



<br/>Radiology<br/>
<br/>


<br/>Pathology<br/>
<br/>
<br/>Impression / Discussion<br/>1.- Prostate Ca  (initial stage T1c) though intermediate unfavorable [REDACTED] score 4+3 = 7, [REDACTED], and PSA 19.3 at presentation, s/p EBRT  and ADT [REDACTED]-[REDACTED]; <br/>- Recurrence since [REDACTED] until [REDACTED] when bone metastases were found, s/p Lupron and Cabozitaxel x1 cycles ( info gap if the patient received Docetaxel prior to cabozitaxel). <br/>Another info gap duration of treatment with either Abiraterone or Xtandi since both of the agents are mentioned in prior records. Lupron stopped in [REDACTED].<br/>- As far as concern the PSA was found to be almost doubled 11.54 ng/ml, prev(6.47 ng/ml),     ([REDACTED]), which is slightly more than that of [REDACTED] (6.3 ng/ml).<br/>- Testosterone 348 ( [REDACTED]) ng/dL ( prev 291, [REDACTED])<br/>-  The latest PSMA/CT/PET scan of the prostate; few enlarged lymph nodes seen in the distal left common iliac, left external iliac and the retroperitoneum most consistent with metastatic adenopathy in this patient with history of prostate cancer and rising PSA levels;<br/>No focal uptake is seen in the prostate gland and correlate with MRI prostate..<br/>No abnormal uptake in the osseous structures to suggest osseous metastasis.<br/>Few tiny subcentimeter pulmonary nodules on the low-dose CT images and follow-up with CT chest [REDACTED]. No prior studies are submitted for comparison<br/>Patient asymptomatic.. <br/>2.- Osteoporosis; patient on prolia (started on [REDACTED]); unconfirmed info for osteoporosis and fx L/S s/p fall; ? of kyphoplasty ( scheduled not done)<br/>3.- CAD, coronary atherosclerosis., CABG in [REDACTED]<br/>4.- Diabetes type 2<br/>5.- Obesity stage 1<br/>6.- Hypothyroidism<br/>7.- HTN<br/>8.- Hyper/dyslipidemia<br/>9.- Compromised physical condition <br/>10.- ED/impotence ( multifactorial) and depression <br/>11.- Candidate for germline mutation analysis in view of his diagnosis of prostate cancer and the sister with brain cancer ( glioblastoma ?) / analysis<br/>Guardant test - evaluate molecular genomics, uncertain if useful at this time<br/>12.- Frequent UTIs<br/>13.- Radiation proctitis and abscess resolved<br/>PS ECOG scale 0<br/>Plan / Recommendations<br/>1-. Continue Prolia<br/>2-. Reassess in 4 mo PSA and CEA <br/>3-. No intervention yet in view of asymptomatic pattern<br/>4-. Maintain monitoring for the rest of the problems<br/>5-. Improve hydration techniques and physical fitness<br/>Diagnosis<br/>- Metastatic prostate cancer<br/>- Osteoporosis<br/>- ED/impotence<br/>- UTI<br/>- Diabetes<br/>- Obesity<br/>- CAD<br/>- HTN<br/>ECOG scalPS 0<br/>  <br/>CC<br/>[REDACTED] M NARA NP-C  <br/>Signature<br/>Note created by [REDACTED] MD, Physician,   <br/>
<br/>Electronically signed by [REDACTED] MD [REDACTED] 04:23 PM PDT 
		        </p>
		      </li></ul>
</div><br/><br/>
</body></html>